BENDECTIN
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jul 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 27m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENDECTIN is an oral extended-release small-molecule tablet approved in 1956 for an unknown indication under an NDA from Sanofi. The mechanism of action and pharmacologic class are not specified in available data. Patient population and therapeutic use cannot be determined from current information.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%), suggesting a declining or niche market with limited team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BENDECTIN offers limited career advancement potential as a legacy product approaching LOE with zero active job openings. Roles available are maintenance-oriented, focused on managed care, compliance, and orderly transition planning rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on BENDECTIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.